In January 2019, Locus entered a collaboration with Janssen Pharmaceuticals, one of Johnson & Johnson's companies, to develop ...

Viatris (VTRS) stock in focus as the company beats Street forecasts with Q3 2025 financials amid strong emerging market growth and raises its outlook. Read more here.

Viatris on Thursday beat Wall Street estimates for third-quarter results, driven by strong demand for its branded drugs in China and emerging markets, and raised its forecasts for 2025 profit and ...

The TL1a inhibitor duvakitug was effective at 14 weeks in patients who had previous exposure to conventional and advanced ...

Viatris Inc. investors can’t proceed with a lawsuit claiming the drugmaker misrepresented its commitment to its biosimilars business segment, the Third Circuit said Thursday.

Medication company Viatris (NASDAQ:VTRS) beat Wall Street’s revenue expectations in Q3 CY2025, but sales were flat year on year at $3.76 billion. The company’s full-year revenue guidance of $14.1 ...

Duvakitug outperformed placebo at week 14 in endoscopic response and was well tolerated among patients with moderately to severely active Crohn’s disease, according to research presented at ACG Annual ...

Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived ...

The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning.

Pfizer won a $10 billion bidding war for Metsera, beating Danish rival Novo Nordisk, securing access to the U. biotech's experimental obesity drug assets.

Pfizer is one of the world's largest pharmaceutical companies. It has a few material patent expirations on the horizon. It's doing what it has to do to deal with that headwind and others. Pfizer is ...

Pfizer's oncology portfolio has produced a second positive phase 3 trial in HER2-positive breast cancer in the span of about a year. This time, the drug that delivered the positive readout is Tukysa, ...